MedTrace Logo

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

NCT05559008 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2022-11-09

No results posted yet for this study

Summary

This is a multicenter, prospective, open-label, interventional umbrella study to evaluate the efficacy and safety of targeted therapies guided by molecular subtypes in patients with relasped or refractory peripheral T-cell lymphoma.

Conditions

  • Peripheral T Cell Lymphoma

Interventions

DRUG

Azacitidine Injection

Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes

DRUG

Dasatinib

Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes

DRUG

Linperlisib

Azacitidine Injection，SC and Linperlisib PO will be administered in T2 subtypes

DRUG

Tucidinostat

Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes

DRUG

SHR2554

Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes

DRUG

Camrelizumab

Camrelizumab and Apatinib will be administered in T3.2 subtypes

DRUG

Apatinib

Camrelizumab and Apatinib will be administered in T3.2 subtypes

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Weili Zhao · Ruijin Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2024-03-26
Completion
2026-01-26

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05559008 on ClinicalTrials.gov